Sanofi trial expert joins Oct. 27 breakfast panel

Tal Zaks, Sanofi's head of development for its Global Oncology Division, will be joining us for the October 27th breakfast in Boston, where we'll be highlighting some of the most recent advances in trial design and execution. Earlier this year Sanofi outlined some big plans for increased R&D work on new cancer drugs, and new operations planned for Cambridge, MA will fit prominently in that aggressive strategy. Zaks has a considerable amount of hands-on trial expertise. He'll be joined in the panel discussion by AstraZeneca's Rick Sax, who's in charge of the pharma company's trial design work, William Slichenmyer at Aveo, another cancer development expert, and Santosh Vetticaden, the Chief Medical and Development Officer from Cubist. I'll be on hand to moderate.

Drop me a line if there's any topic or question you would like to suggest for the discussion.

The breakfast is sponsored by INC Research and PAREXEL and the Massachusetts Life Sciences Center is helping to get the word out. Click here to register for the breakfast. - John Carroll (twitter | email)

P.S. San Francisco Bay Area readers: Our publisher Arsalan Arif (e-mail | twitter) is hosting an informal FierceBiotech happy hour downtown from 4:30 to 7:30p at Rickhouse Bar (directions). This is an excellent chance to network with other local readers, so if you're in the area please drop by.

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.